1
/
of
2
Atenurix (Febuxostat)
Atenurix (Febuxostat)
Regular price
₱915.00 PHP
Regular price
Sale price
₱915.00 PHP
Unit price
₱30.50 each
Taxes included.
Quantity
Couldn't load pickup availability
Atenurix Febuxostat is a prescription medication used to manage chronic gout by lowering uric acid levels in the body. Febuxostat is a xanthine oxidase inhibitor that reduces the production of uric acid, helping prevent gout attacks, tophi formation, and joint damage associated with hyperuricemia.
This medication is indicated for patients with chronic gout who experience recurrent acute attacks or have developed chronic tophaceous gout. It is particularly beneficial for those who cannot tolerate allopurinol or require an alternative xanthine oxidase inhibitor due to contraindications or inadequate response to other urate-lowering therapies.
Atenurix Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for converting hypoxanthine and xanthine to uric acid. By reducing serum uric acid concentrations, the medication helps dissolve existing uric acid deposits and prevents new crystal formation in joints and surrounding tissues.
The typical dosage regimen involves starting with a lower dose and titrating based on serum uric acid levels and clinical response. Treatment goals usually target serum uric acid levels below 6 mg/dL to achieve gout remission and prevent disease progression. Regular monitoring through laboratory tests is recommended to ensure therapeutic efficacy and safety.
Common considerations include potential drug interactions, contraindications in patients with severe hepatic or renal impairment, and the need for concurrent prophylaxis with NSAIDs or colchicine during the initial months of treatment to prevent acute flares. Patients should follow their healthcare provider's instructions regarding dosage, monitoring requirements, and lifestyle modifications including dietary purine restriction and adequate hydration.
Atenurix Febuxostat is a reliable option for long-term gout management when prescribed and monitored appropriately by qualified healthcare professionals.
This medication is indicated for patients with chronic gout who experience recurrent acute attacks or have developed chronic tophaceous gout. It is particularly beneficial for those who cannot tolerate allopurinol or require an alternative xanthine oxidase inhibitor due to contraindications or inadequate response to other urate-lowering therapies.
Atenurix Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for converting hypoxanthine and xanthine to uric acid. By reducing serum uric acid concentrations, the medication helps dissolve existing uric acid deposits and prevents new crystal formation in joints and surrounding tissues.
The typical dosage regimen involves starting with a lower dose and titrating based on serum uric acid levels and clinical response. Treatment goals usually target serum uric acid levels below 6 mg/dL to achieve gout remission and prevent disease progression. Regular monitoring through laboratory tests is recommended to ensure therapeutic efficacy and safety.
Common considerations include potential drug interactions, contraindications in patients with severe hepatic or renal impairment, and the need for concurrent prophylaxis with NSAIDs or colchicine during the initial months of treatment to prevent acute flares. Patients should follow their healthcare provider's instructions regarding dosage, monitoring requirements, and lifestyle modifications including dietary purine restriction and adequate hydration.
Atenurix Febuxostat is a reliable option for long-term gout management when prescribed and monitored appropriately by qualified healthcare professionals.
Share
